A groundbreaking leukaemia supplement developed by a research team from Universiti Kuala Lumpur Royal College of Medicine Perak (UniKL RCMP) has clinched the first runner-up position at the prestigious Swiss Innovation Challenge Malaysia 2025 (SIC 2025).
The recognition was awarded during the grand finale held on 24 September 2025, honouring the flagship project “β-CAPS+: A Natural Leap in Leukaemia Treatment.”
The project was led by ChM. Dr. Mazlin Mohideen from UniKL RCMP in collaboration with Dr. Nur Azzalia Kamaruzaman from Pusat Racun Negara, Universiti Sains Malaysia.
This partnership highlights the importance of cross-institutional collaboration in transforming research excellence into impactful healthcare solutions.
“This achievement showcases UniKL RCMP’s dedication to turning innovative research into practical solutions that benefit society.
“β-CAPS+ is not only a scientific breakthrough but also a step towards Malaysia’s vision of becoming a global player in healthcare innovation,” said ChM. Dr. Mazlin Mohideen.
SIC 2025 marked the culmination of a three-stage pitching competition that brought together leading innovators, entrepreneurs, and researchers from across Malaysia.
With its chemopreventive and neuroprotective potential, β-CAPS+ demonstrates Malaysia’s capability to contribute meaningfully to SDG 3 (Good Health and Well-being) and SDG 9 (Industry, Innovation, and Infrastructure), while aligning with the nation’s Ekonomi MADANI and MySTIE 10-10 frameworks.
Developed from β-carboline extracted from Neolitsea kedahensis, a rare plant endemic to Gunung Jerai, Kedah, β-CAPS+ offers a cost-effective solution with proven anticancer and neuroprotective properties, specifically targeting leukaemia.
